GSK to Buy Antibody Treatment From Chimagen for Up to $750 Million
(06:00 GMT) *GSK PLC to Buy T Cell-Engager for Multiple Myeloma (06:01 GMT) *GSK PLC: Agreement Has a Total Potential Value of Up to $750M (06:04 GMT) *GSK to Buy TCE for Multiple Myeloma from Chimagen Biosciences (06:05 GMT) *GSK: Program to Enter Clinic in 2027 (06:05 GMT) *GSK: Deal Aligned to P…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.